Methisazone therapy in pediatric vaccinia complications.

Abstract

Methisazone 40 mg/kg/day was administered orally to six pediatric and one adult patient who contracted vesicular complications affecting the skin or mucocutaneous junctions 3 to 9 days after antismallpox vaccination, and to one elderly man with myeloid leukemia who developed vaccinia necrosum. Therapy was commenced 2 to 10 days after onset of complications and was administered for 3 days. All patients with skin or mucocutaneous complications showed dramatic clinical responses within one day after commencement of antiviral chemotherapy, and complete recovery occurred within one week. Clinical improvement was noted 4 days after therapy was begun in the case of vaccinia necrosum, and recovery occurred after 3 weeks.

• Authors: D M McLean
• Journal: Annals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 284 Pg. 118-21 (Mar 04 1977) ISSN: 0077-8923 [Print] United States
• PMID: 280134 (Publication Type: Journal Article)

Chemical References

• Thiosemicarbazones
• Methisazone

Topics

• Adult
• Aged
• Child
• Child, Preschool
• Humans
• Infant
• Methisazone (therapeutic use)
• Necrosis
• Skin Diseases, Infectious (drug therapy, pathology)
• Thiosemicarbazones (therapeutic use)
• Vaccinia (drug therapy)